TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Ratio of Nerve Fluorescence compared to Background Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NP-G2-044 anti-tumor preliminary efficacy signals when administered as continuously dosed monotherapy assessed by RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: NP-G2-044 anti-tumor preliminary efficacy signals when administered in combination with anti-PD-1 therapy assessed by RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 monotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 and anti-PD-1 combination therapy
Endpoint domain: Adverse events/effects
Primary endpoint: mHLA DR expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recruitment rate/consent rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients who find DIALOG and DIALOG+ feasible and acceptable
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mood relapses
Endpoint domain: Adverse events/effects
Primary endpoint: Disability (Shoulder And Pain Disability Index)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disability (Victorian Institute of Sport Assessment - Patellar)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disability (Victorian Institute of Sport Assessment - Achilles)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain (Visual Analogue Scale)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Amino acid profile in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of time spent in optimal SpO2 range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cardiovascular Hospitalization or Death
Endpoint domain: Mortality/survival
Primary endpoint: Change in Experiential Negative Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recommended Phase 2 Dose (RP2D) of selinexor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in Forced Vital Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of women with CIN2+ diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of women with CIN3+ diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Use of Any Evidence-Based Cessation Treatments (EBCTs)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Interleukin 6 (IL6) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progression Free Survival (PFS) rate at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Connor Davidson Resilience Scale (CDRISC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Need for catheter adjustment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Parent-Child Interaction Quality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent change in bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Infusion Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of Infusion Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of ATTR PN in patients with CTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol use - Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol Use - Quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phosphatidylethanol (PEth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of TMP-301 as assessed by the Timeline to Followback measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in number of medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in Forced expiratory volume in the first second of expiration (FEV₁)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Forced vital capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in FEV₁ / FVC index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ATX and LPA levels in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of adverse events with Sonazoid
Endpoint domain: Adverse events/effects
Primary endpoint: Number of in-hospital days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change From Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes of Body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac Biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Doppler resistant index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time spent with glucose in the target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in average daytime ambulatory systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subject level composite of the incidence of Major Adverse Events (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Central Sensitization Inventory (CSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure-Pain Threshold (PPT) Using Algometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stabilization or disease improvement rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Eating Assessment Tool-10 (EAT-10)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Body weight reduction ≥ 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AHI and Desaturations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cytomegalovirus disease
Endpoint domain: Adverse events/effects
Primary endpoint: Herpesvirus human 6 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Herpesvirus human 6 disease
Endpoint domain: Adverse events/effects
Primary endpoint: Virus Epstein-Barr infection
Endpoint domain: Adverse events/effects
Primary endpoint: Virus Epstein-Barr disease
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of toolkit use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant satisfaction with toolkit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of adverse events and injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Return visits or readmissions to the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Thrombospondin-4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who achieved complete remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in hepatic fat fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects with ≥ 30% relative fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in cycloplegic spherical equivalent refractive error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of spontaneous pregnancy with live-born children
Endpoint domain: Life impact
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Progression Free Survival at 24 months (PFS24)
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants who receive HPV vaccination
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants who Develop MAKE90
Endpoint domain: Mortality/survival
Primary endpoint: G-quadruplex DNAm score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rivermead post-concussion questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HADS-scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of pro-inflammatory and anti-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: First recurrence of colorectal cancer with liver metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Plasma metabolite concentration at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine metabolite concentration at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in relative abundance of AGR2 mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expressed gene transcripts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composition of immune cell subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Achievement of treatment response (rCRISS50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain hemodynamic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optical properties of the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image quality adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight estimation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug dose accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective experience of unpleasantness associated with sensations of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective experience of unpleasantness associated with sensations of physical effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharyngocutaneous fistula occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage change in serum creatine kinase (CK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Deficit of declarative memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brier Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Log-Loss Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Precision-Recall Curves (AUCPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reference range intervals of PSP values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of procedures where the device operated as intended
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Marginal Bone Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fractal values around dental implant radiographs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suckling performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Star Balance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tegner Activity Level Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: KOOS-PS (Knee Injury and Osteoarthritis Outcome Score - Physical Function Short Form)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: WOMET (Western Ontario Meniscal Evaluation Tool)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Difference in VO2peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from clinically-driven target lesion revascularization (CD-TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Major Adverse Limb Event (MALE) at 6 months
Endpoint domain: Adverse events/effects
Primary endpoint: Peri-Operative Death (POD) at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Positive plectin staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of reactive steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity measured by NCI-CTCAE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Solicited Local (Injection Site) Adverse Events by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Solicited Systemic Adverse Events by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with a Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Area under ROC curve of MTB cfDNA assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Needs reported by children
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Impaired cognitive status
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Recruitment and Retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: EEG SEF95 value for oral pacifier response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG SEF95 value for electrical stimulation response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG SEF95 value for laryngoscopy response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of leukopenia and neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in post-dose spirometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Achieving IST Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants without progression after 9 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended dose range (RDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitochondrial dysfunction characterized by bioenergetic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Satisfaction Questionnaire for Medication-11 (TSQM-11) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: World Health Organisation Well-Being Index (WHO-5) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Liver-related Composite Clinical Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality indicators specific to triage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change from Baseline of Urine Albumin-Creatinine Ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent of participants with ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Rustogi Modifiye Navy Plaque Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients receiving targeted therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients achieving HiSCR75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in dynamic R2*-weighted signal (BOLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence of preoperative malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Performance of the PureWick System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the PureWick System
Endpoint domain: Adverse events/effects
Primary endpoint: virological relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain of Local Anesthetic Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in advance care planning preparedness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in patients' engagement in advance care planning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in knowledge about dementia trajectory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pediatric Quality of Life Inventory (PedsQL) Cancer Module
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Child Fatigue Scale-R 24-Hours
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Pain Flexibility Scale for Children with Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Muscular Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Very Good Partial Response (VGPR) or better
Endpoint domain: Physiological/clinical
Primary endpoint: Change in European Quality of Life-5 Dimensions questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Skeletal Burden Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with severe adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in tear meniscus height (TMH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-C Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Probability of recruiting 30 eligible patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Probability of participant attendance at ≥60% of exercise sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Probability of instructors rating the platform as acceptable
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Presence of lesions expressing SST2 receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical sensitivity for self-collected samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical sensitivity for clinician-collected samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical specificity for self-collected samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in amblyopic eye visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects to experience significant improvement from implantation of the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Vestibular pain index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic valve tissue composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of respiratory support in newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Uroflow results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bladder scan results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cumulative vasopressor dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cut-off value for FeNO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound Healing Assessment Tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Event Reporting Form
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of heavy drinking days
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Engagement in HIV prevention or treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: muscular activity of the shoulder sectors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes